GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (NAS:ENTO) » Definitions » Net Intangibles Purchase And Sale

ENTO (Entero Therapeutics) Net Intangibles Purchase And Sale : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Entero Therapeutics Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Entero Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2025 was $0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Entero Therapeutics Net Intangibles Purchase And Sale Historical Data

The historical data trend for Entero Therapeutics's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entero Therapeutics Net Intangibles Purchase And Sale Chart

Entero Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -10.25 - -0.50 -

Entero Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Entero Therapeutics Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entero Therapeutics Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (NAS:ENTO) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
VCNX GRTX OCEA OMGAQ SILO SLRX AGTX AXIM ADTX BPTH VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
Website
https://www.enterothera.com
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Executives
Sarah Romano officer: Chief Financial Officer 271 WAVERLY OAKS ROAD, WALTHAM MA 02452
James Sapirstein director, officer: President and CEO 1517 SAN JACINTO, HOUSTON TX 77002
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman director 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell director C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm director 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes director 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington officer: CHIEF MEDICAL OFFICER 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman officer: CHIEF FINANCIAL OFFICER 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr. 10 percent owner C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor director, officer: President and CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc 10 percent owner PO BOX 2422, WESTPORT CT 06880